Invasive pneumococcal disease (IPD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Invasive pneumococcal disease is defined as an infection confirmed by the isolation of Streptococcus pneumoniae from a normally sterile site (eg, blood, cerebrospinal fluid, and pleural, joint, or peritoneal fluid but not sputum). Children with pneumococcal infection often present with non-specific symptoms and signs including isolated fever. Certain populations of children are at increased risk of IPD. Children at particularly high risk are those with antibody deficiencies, such as X-linked (Bruton's) agammaglobulinemia, anatomic or functional asplenia, sickle cell disease, HIV infection, and those with cochlear implants or CSF leak. Children with other chronic illnesses (eg, cardiac, pulmonary, or renal disease and diabetes mellitus) and those receiving chemotherapy or steroids are also at risk. Children in daycare from an early age also have a higher incidence of IPD. Around 10–20% of children with pneumococcal meningitis have underlying comorbidity. The manifestations of IPD are; Bacteremia, Pneumonia, Meningitis, Cellulitis, Sinusitis, Septic arthritis, Peritonitis, Otitis media, and Others. Bacteremia and pneumonia were most common and the pneumonia patients by definition were bacteremic. Otherwise, meningitis was the most common manifestation of IPD (4.9%) while endocarditis/pericarditis was the least common (<1%).

  • The incidence of invasive pneumococcal disease in any population is affected by geographic location, time of year, serotype prevalence, age, comorbidities, and vaccination status. The highest incidence of the invasive pneumococcal disease occurs in adults ≥65 years of age, in children <2 years of age, and in those with certain underlying conditions, such as HIV infection.
  • The incidence of invasive pneumococcal disease in individuals ≥65 years of age was 36.4 cases per 100,000 population and, in infants <1 year, the incidence was 34.2 cases per 100,000 population, compared with 3.8 cases per 100,000 population in individuals between 18 and 34 years of age.

The competitive landscape of Invasive pneumococcal disease (IPD) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Invasive pneumococcal disease (IPD) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Invasive pneumococcal disease (IPD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Invasive pneumococcal disease (IPD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset   Company         Stage

1          13-valent pneumococcal conjugate vaccine (13vPnC)     Wyeth            Phase 3

2          Pneumococcal conjugate vaccine GSK1024850A            GlaxoSmithKline            Phase 3

3          VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine)            Merck Sharp & Dohme Corp.     Phase 2/3

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more